3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Machado-Joseph Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfonso, IL; Berciano, J; Ceberio, JI; Cubo, E; Iglesias, F; López, MD; Martinez, BM; Obeso, JA | 1 |
| Buhmann, C; Bussopulos, A; Oechsner, M | 1 |
2 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Machado-Joseph Disease
| Article | Year |
|---|---|
Striatal dopamine function in a family with multiple SCA-3 phenotypes.
Topics: Aged; Benzamides; Corpus Striatum; Dopamine; Female; Humans; Machado-Joseph Disease; Male; Middle Aged; Pedigree; Phenotype; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon; Tropanes | 2011 |
Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease.
Topics: Atrophy; Basal Ganglia; Benzamides; Cerebellum; Contrast Media; Corpus Striatum; Dopamine Agonists; Humans; Machado-Joseph Disease; Magnetic Resonance Imaging; Male; Middle Aged; Occipital Lobe; Parkinsonian Disorders; Phenotype; Pons; Pyrrolidines; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2003 |